Assessment of physical and dissolution characteristics of various itraconazole capsule formulations: a comparative analysis

Rajan Verma*, Shrikant Hodge, Chandrashekhar Gargote, Prakash Modi, Naresh Upreti, Lokesh Yadav, Raviraj Pillai

Innovation and Development, Abbott Healthcare Pvt. Ltd., Mumbai, India

Received: 06 May 2019
Accepted: 20 June 2019

*Correspondence:
Dr. Rajan Verma,
E-mail: rajan.k.verma@abbott.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Background: This in vitro study compared physical parameters and the dissolution profile of innovator itraconazole capsule formulation, i-Tyza, and 5 other generic capsule formulations available in the Indian market.

Methods: The number of pellets and size distribution were determined using naked eye examination and sieving method, respectively. Dissolution profile of formulations was done at 15, 30, 45, and 60 minutes, using a United States Pharmacopeia type II Paddle apparatus in simulated gastric fluid (SGF, pH 1.2) without enzymes, acetate buffer (pH 4.5) with 0.5% sodium lauryl sulfate (SLS), and phosphate buffer (pH 6.8) with 0.5% SLS.

Results: All formulations had capsule size 0. Capsule fill weight (~335 to ~510 mg) and total pellet number (127 to 810) varied across formulation, with the innovator brand having the highest number of pellets. Innovator product and i-Tyza had similar fill weight (~460 mg). Pellet size distribution of the innovator product, brand 2, brand 3, and i-Tyza was relatively narrow. In SGF, except brand 1 (84% dissolved) and brand 5 (80% dissolved), all the formulations had near-complete (>85% drug dissolved) or complete dissolution (>90% drug dissolved) at 60 minutes. In acetate buffer, pH 4.5 with 0.5% SLS and phosphate buffer, pH 6.8 with 0.5% SLS, only the innovator product and i-Tyza demonstrated near-complete to complete dissolution at 60 minutes (96% and 90% dissolved).

Conclusions: Across all the itraconazole generic formulations evaluated, i-Tyza had comparable physical characteristics and dissolution profile to the innovator product. The in vitro dissolution profile of i-Tyza may indicate adequate in vivo performance.

Keywords: Itraconazole, i-Tyza, BCS class II, Capsule, Pellet, Dissolution profile, Physical characterization

INTRODUCTION

Dermatophytosis is one of the most common fungal infections, transmitted through direct skin contact with other infected humans or animals or indirect contact through communal bathing facilities, shoes, clothes, brushes, etc. The global prevalence of dermatophytosis ranges between 6.5-68%. In India, the prevalence of dermatophytosis is very high (62.28%-75.6%). Expert consensus on The Management of Dermatophytosis recommends itraconazole as one of the preferred drugs for the systemic treatment of Indian patients with dermatophytosis. Itraconazole is a potent broad-spectrum, triazole antifungal drug; it inhibits the sterol biosynthesis in the fungal cell membrane. However, evidence suggests that orally administered itraconazole may have inconsistent bioavailability and interindividual variations. Few reports have suggested that substitution of proprietary itraconazole formulation with the generic formulation demonstrated sub-therapeutic levels of the drug in patients, causing treatment failure and drug resistance.
Itraconazole belongs to Biopharmaceutics classification system (BCS) class II, with low solubility (aqueous solubility: 1 ng/ml at pH 7 and 5 µg/ml at pH 1) and high permeability. For BCS class II molecules, the dissolution of drug in the gastrointestinal tract could be the rate-limiting step in absorption into the systemic circulation. Thus, the antifungal activity and treatment outcome of itraconazole largely depends on the formulation behavior. For enhancement of aqueous solubility, dissolution rate and bioavailability of BCS class II drugs, techniques such as micronization, chemical modification, pH adjustment, solid dispersion, complexation are often employed. To improve the dissolution profile of itraconazole, the innovator product is prepared by solid dispersion technology by coating inert beads or pellets (600–710 µm) with itraconazole and hydrophilic polymer (hydroxypropyl methylcellulose). Pellets provide a large surface area for dissolution, thereby improving the absorption of itraconazole into the systemic circulation. Hence, evaluation of pellet size and size variation is essential to determine the quality of formulations. Additionally, other parameters in the formulation such as the drug-polymer ratio, solvent composition, coating spray rate and temperature in the fluidized bed are also crucial to obtain good quality products. To ensure quality and reproducibility and to minimize the number of in vivo studies, in vitro dissolution tests mimicking the in vivo gastrointestinal hydrodynamics are usually applied. To this effect, in vitro tests such as dissolution studies in multiple media are performed to predict performance of the products in vivo.

In this study, we compared the physical parameters and dissolution profile of the innovator itraconazole capsule formulation and 6 other generic capsule formulations: i-Tyza (Abbott Healthcare Pvt. Ltd.), brand 1, brand 2, brand 3, brand 4, and brand 5.

METHODS

Seven brands of itraconazole capsule (100 mg) currently marketed and prescribed by health care professionals from India were included in this in vitro study to compare their physical characteristics and dissolution profile, across formulations. A bio-relevant dissolution test was used to identify the pellet formulation that demonstrated an optimal dissolution profile across the pH simulating the gastrointestinal tract. As the study did not involve human subjects, ethical approval was not needed to conduct this study.

Physical characterization

Physical characterization involved determination of the capsule size, fill weight, total number of pellets, number of active pellets, number of dummy pellets, and pellet size distribution. Distinction between active and dummy pellets and the count of total pellet number was done by naked eye examination and pellet size was determined by

the sieving method. Sieve analysis was performed by arranging sieves in the order of their decreasing pore diameter. Pellet sizes were stratified per American Society of Testing and Material (ASTM) standards: ASTM #14 (1405 µm), ASTM #16 (1204 µm), ASTM #18 (1003 µm), ASTM #20 (850 µm), ASTM #25 (710 µm).

Dissolution profiling

Dissolution test of itraconazole capsule was performed using a United States Pharmacopeia type II (Paddle) apparatus (Labindia Analytical Instruments), at 37°C±0.5°C, 100 rpm in simulated gastric fluid (SGF, 900 ml, pH 1.2) without enzyme, acetate buffer (pH 4.5+0.5% sodium lauryl sulfate [SLS], 900 ml), and phosphate buffer (pH 6.8+0.5% SLS, 900 ml). One itraconazole capsule was added to each of the 6 dissolution vessels and 10 ml aliquots were withdrawn at 15, 30, 45, and 60 minutes. All aliquots were filtered through 0.45 µm nylon membrane and analyzed using high-performance liquid chromatography (HPLC). For HPLC analysis, reverse phase column (Hypersil BDS C18, 150 mm × 4.6 mm, 5 µm, maintained at 25°C), mobile phase (buffer: acetonitrile of 65:35 [v/v]; flow rate 1.5 ml/min), and isocratic flow was used. During analysis, a 50 µl sample was run for 12 minutes and results were read at 225 nm. A standard itraconazole solution of 0.111 mg/ml concentration was prepared for analysis in methanol and hydrochloric acid followed by SGF without enzymes. A blank solution (dissolution medium only), standard solutions (5 replicates) and sample aliquots were injected in the HPLC system and the response of itraconazole in standard and sample solutions was measured. Percentage itraconazole release from itraconazole capsule at each time interval was calculated accordingly.

RESULTS

Physical characterization

All the formulations had a similar capsule size 0. However, capsule fill weight (~335 to ~510 mg) and the total number of pellets (127 to 810) varied across formulations. The innovator formulation and i-Tyza had almost similar fill weight (~460 mg). The innovator product also had the highest pellet number (810), followed by brand 4 (690), brand 5 (570), i-Tyza (510), and brand 1 (435). High fill weight but low pellet number were seen in brands 2 and 3 (509 mg and 127 pellets, and 508 mg and 128 pellets, respectively.

In addition to the low pellet size, the innovator formulation also had narrow pellet size distribution, with 94.27% pellets retained on sieve number 20 (850 µm). Particle size distribution of the innovator formulation, brand 2, brand 3 and i-Tyza was relatively narrow (Table 1). All the formulations had only active pellets and none of the selected formulations included dummy pellets.
Table 1: Physical parameters of different itraconazole formulations.

| Products | Innovator | Brand 1 | Brand 2 | Brand 3 | Brand 4 | Brand 5 | i-Tyza |
|----------|-----------|---------|---------|---------|---------|---------|-------|
| Capsule size | Size 0 | Size 0 | Size 0 | Size 0 | Size 0 | Size 0 | Size 0 |
| Fill weight (mg) | ~460 | ~335 | ~509 | ~508 | ~510 | ~485 | ~460 |
| Total no. of pellets | 810 | 435 | 127 | 128 | 690 | 570 | 510 |
| No. of active pellets | 810 | 435 | 127 | 128 | 690 | 570 | 510 |
| No. of dummy pellets | - | - | - | - | - | - | - |
| Pellet size distribution | % retained | | | | | | |
| ASTM # 14 (1405µm) | 0.00 | 0.00 | 98.17 | 96.82 | 0.00 | 0.00 | 0.00 |
| ASTM # 16 (1204µm) | 0.39 | 0.00 | 1.83 | 3.18 | 0.00 | 0.92 | 1.09 |
| ASTM # 18 (1003µm) | 2.08 | 37.01 | - | - | 60.25 | 35.32 | 19.51 |
| ASTM # 20 (850µm) | 94.27 | 46.27 | - | - | 78.58 | 87.90 | 10.53 |
| ASTM # 25 (710µm) | 3.27 | 16.72 | - | - | 4.43 | 0.99 | 0.47 |

ASTM: American Society for Testing and Materials; Based on visual observation, there were no dummy pellets in any formulation.

Table 2 (A): Dissolution profile of different itraconazole formulations in simulated gastric fluid, pH 1.2 without enzymes.

| Products | Mean % drug release | Time (minutes) |
|----------|---------------------|----------------|
| Innovator | Brand 1 | Brand 2 | Brand 3 | Brand 4 | Brand 5 | i-Tyza |
| 15 | 39 | 5 | 37 | 23 | 60 | 1 | 39 |
| 30 | 63 | 23 | 79 | 76 | 96 | 18 | 81 |
| 45 | 79 | 60 | 98 | 99 | 102 | 59 | 97 |
| 60 | 89 | 84 | 100 | 102 | 104 | 80 | 102 |

Mean values are obtained from 6 units. For Brand 1, values were obtained from 5 units.

Table 2 (B): Dissolution profile of different itraconazole formulations in acetate buffer pH 4.5 with 0.5% sodium lauryl sulfate.

| Products | Mean % drug release | Time (minutes) |
|----------|---------------------|----------------|
| Innovator | Brand 1 | Brand 2 | Brand 3 | Brand 4 | Brand 5 | i-Tyza |
| 15 | 18 | 11 | 5 | 6 | 5 | 3 | 22 |
| 30 | 49 | 71 | 33 | 35 | 18 | 35 | 64 |
| 45 | 75 | 82 | 52 | 58 | 33 | 51 | 92 |
| 60 | 88 | 86 | 64 | 69 | 43 | 77 | 98 |

Mean values are obtained from 6 units.

Table 2 (C): Dissolution profile of different itraconazole formulations in phosphate buffer pH 6.8 with 0.5% sodium lauryl sulfate.

| Products | Mean % drug release | Time (minutes) |
|----------|---------------------|----------------|
| Innovator | Brand 1 | Brand 2 | Brand 3 | Brand 4 | Brand 5 | i-Tyza |
| 15 | 21 | 2 | 4 | 2 | 4 | 8 | 16 |
| 30 | 56 | 17 | 17 | 10 | 16 | 20 | 46 |
| 45 | 83 | 35 | 30 | 19 | 30 | 50 | 81 |
| 60 | 96 | 46 | 37 | 26 | 43 | 78 | 90 |

Mean values are obtained from 6 units.

**Dissolution profiling**

In the SGF medium, all the other formulations had near-complete (>85% drug dissolved) or complete dissolution (>90% drug dissolved) at 60 minutes, except for brand 1 (percent dissolved: 84%) and brand 5 (percent dissolved: 80%). In acetate buffer medium (pH 4.5 with 0.5% SLS), only the innovator product (percent dissolved: 88%) and i-Tyza (percent dissolved: 98%) had near-complete or complete dissolution at 60 minutes. Similarly, in phosphate buffer medium (pH 6.8 with 0.5% SLS), only the innovator product (percent dissolved: 96%) and i-Tyza (percent dissolved: 90%) achieved complete dissolution at 60 minutes (Table 2, Figure 1).
International Journal of Research in Dermatology | October-December 2019 | Vol 5 | Issue 4  Page 768

Figure 1 (A): Comparative dissolution profile of different itraconazole formulations in simulated gastric fluid, pH 1.2 without enzymes.

Figure 1 (B): Comparative dissolution profile of different itraconazole formulations in acetate buffer with 0.5% SLS (pH 4.5).

Figure 1 (C): Comparative dissolution profile of different itraconazole formulations in phosphate buffer with 0.5% SLS (pH 6.8).

DISCUSSION

This study compared the physical parameters and dissolution profile of various itraconazole capsule formulations routinely prescribed by health care professionals for treating dermatophytosis. This is essential as poor bioavailability may have an impact on the clinical outcomes. We found that the innovator product had a high pellet number, and low fill weight and pellet size variation. These physical characteristics were comparable with 2 generic formulations, i-Tyza and brand 5. However, compared with brand 5, dissolution profiles of i-Tyza were better across all the dissolution media. Thus, our results suggest that compared with other itraconazole formulations, the physical parameters and dissolution profile of i-Tyza have a greater similarity with the corresponding parameters of the innovator product.

Itraconazole is a preferred, orally administered drug for the treatment of dermatophytosis. However, its bioavailability and, in turn, efficacy may vary with formulation change because of its physicochemical properties (low solubility) and formulation-dependent factors such as the drug-polymer ratio, solvent composition, pellet size. Hence, an itraconazole formulation (pellets) with an optimal dissolution profile is essential for adequate treatment response.

In this study, the innovator product had the smallest pellet size, with majority of pellets falling in the range of 850 µm to 1003 µm. The pellet size of generic formulations, i-Tyza, brand 5, and brand 4 was closer to that of the innovator product with majority of the pellets in the size range of 850-1204 µm. However, among the generic formulations, least pellet size variation was observed for i-Tyza. In another morphometric study that compared the innovator product with 21 other generic formulations, similar results were observed for the innovator product (average pellet size 969 µm and pellet size range 893-1184 µm). Pellet size variability is a parameter that indicates the quality of formulation. High variability is indicative of poor quality formulation and, in turn, variable dissolution profile. Drugs with less pellet size variation may have less erratic gastrointestinal absorption profile. Hence, poor physical parameters may cause erratic absorption and adversely affect bioavailability.

In the present study, pellet number was highest for the innovator product, followed by brand 4, brand 5, and i-Tyza. A similar result for the pellet number of the innovator product was observed by Sardana et al (2018). The authors also reported a large variation in pellet number and average pellet size among different brands, however the authors did not perform the dissolution studies. Dissolution of itraconazole from drug product is critical for clinical performance and it depends not only on pellet number but also on pellet size and manufacturing technology. Despite having differences in pellet number, i-Tyza demonstrates comparable dissolution with innovator product. This was made possible by carefully selecting the drug-polymer ratio and also precisely controlled and robust manufacturing process.

The United States Food and Drug Administration guidelines for dissolution testing of immediate-release solid oral dosage forms recommend that drugs belonging to BCS class I or III and having high solubility, 85% dissolution in SGF in 15 minutes ensures that bioavailability is not dissolution dependent. However, for BCS class II drugs, such as itraconazole, dissolution is a rate-limiting step for absorption; hence, dissolution...
profile in multiple media is recommended to establish an in vitro-in vivo correlation.\textsuperscript{24} In this study, we assessed the dissolution profile of itraconazole formulations in SGF without enzymes, acetate buffer, pH 4.5 with 0.5% SLS, and phosphate buffer, pH 6.8 with 0.5% SLS, which mimic the pH conditions in the stomach and intestines. In SGF without enzymes, the innovator product, i-Tyza, brand 2, brand 3, and brand 4 had near-complete dissolution at 60 minutes. In the acetate buffer, pH 4.5, only i-Tyza (percent dissolved: 98%) and the innovator product (percent dissolved: 88%) had a near-complete dissolution at 60 minutes. In phosphate buffer, pH 6.8, only i-Tyza showed complete dissolution similar to that of the innovator product. Biorelevant in vitro dissolution is a useful technique for qualitative forecasting of the in vivo behavior of a formulation. Considering the site of absorption of itraconazole, phosphate buffer, pH 6.8 with 0.5% SLS can be considered as a biorelevant media. The dissolution profile of i-Tyza was similar to that of the innovator product in phosphate buffer, pH 6.8 with 0.5% SLS with 96% and 90% dissolution at 60 minutes, respectively, giving a high degree of assurance of similar in vivo performance.

The study had few limitations. We assessed the samples from a single batch, hence inter-batch variability of formulations could not be ruled out. Furthermore, statistical analyses were not done to compare the physical profile of the formulations; hence determination of statistical significance of the comparisons across formulations was not possible.

CONCLUSION

A novel formulation of itraconazole, i-Tyza, had comparable quality to that of the innovator product. The physical parameters and dissolution profiles of i-Tyza were relatively favourable compared with those of other generic formulations available in the Indian market.

ACKNOWLEDGEMENTS

Rahul Nikam (Sciformix, a Covance Company) provided writing assistance and Dr Shalini Nair (Abbott) provided additional scientific review and editorial support for the development of this manuscript.

Funding: The study was funded by Abbott Healthcare Pvt. Ltd., Mumbai, India
Conflict of interest: None declared
Ethical approval: Not required

REFERENCES

1. Clemons KV, Richardson MD. Chapter 7-Pathways and routes of natural exposure to fungal infection. In: Viegas C, Pinheiro AC, Sabino R, Viegas S, Brandão J, Veríssimo C, eds. Environmental Mycology in Public Health Fungi and Mycotoxins: Risk Assessment and Management. Academic Press; 2016: 65-76.
2. Bitew A. Dermatophytosis: prevalence of dermatophytes and non-dermatophyte fungi from patients attending Arsho Advanced Medical Laboratory, Addis Ababa, Ethiopia. Dermatol Res Pract. 2018:8164757.
3. Avancini J, Zucchi P. Prevalence of dermatoses in patients referred for evaluation in an outpatient clinic of specialties. An Bras Dermatol. 2018;93:513-6.
4. Fallahi AA, Rezaei-Mateholaei A, Rezaei S. Epidemiological status of dermatophytosis in Guilan, north of Iran. Curr Med Mycol. 2017;3:20-4.
5. Ismail MT, Al-Kafri A. Epidemiological survey of dermatophytosis in Damascus, Syria, from 2008 to 2016. Curr Med Mycol. 2016;2:32-6.
6. Nweze EI, Eke IE. Dermatophytes and dermatophytosis in the eastern and southern parts of Africa. Med Mycol. 2018;56:13-28.
7. Patwardhan N, Dave R. Dermatomycosis in and around Aurangabad. Indian J Pathol Microbiol. 1999;42:455-62.
8. Lakshmanan A, Ganeshkumar P, Mohan SR, Hemamalini M, Madhavan R. Epidemiological and clinical pattern of dermatomycoses in rural India. Indian J Med Microbiol. 2015;33:134-6.
9. Tripathy S. Rising prevalence of dermatophytosis in India: a matter of concern. Int J Infect Dis. 2016;45:318.
10. Sudha M, Ramani CP, Anandan H. Prevalence of dermatophytosis in patients in a tertiary care centre. Int J Contemporary Med Res. 2016;3:2399-401.
11. Rajagopalan M, Inamadar A, Mittal A, Miskeen AK, Srinivas CR, Sardana K, et al. Expert consensus on The Management of Dermatophytosis in India (ECTODERM India). BMC Dermatol. 2018;18:6.
12. Odds FC, Oris M, Van Dorselaer P, Van Gerven F. Activities of an intravenous formulation of itraconazole in experimental disseminated Aspergillus, Candida, and Cryptococcus infections. Antimicrob Agent Chemother. 2000;44:3180-3.
13. Heykants J, Michiels M, Meulders W, Monabaliu J, Lavrisjen K, Van Peer A, et al. The pharmacokinetics of itraconazole in animals and man: an overview. Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents. Prous Science Publishers; 1989: 223-49.
14. Heykants J, Van Peer A, Van de Velde V, Van Rooy P, Meulders W, Lavrisjen K, et al. The clinical pharmacokinetics of itraconazole: an overview. Mycoses. 1989;32(S1):67-87.
15. Haria M, Bryson HM, Goa KL. Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Drugs. 1996;51:585-620.
16. Pasqualotto AC, Denning DW. Generic substitution of itraconazole resulting in sub therapeutic levels

International Journal of Research in Dermatology | October-December 2019 | Vol 5 | Issue 4 | Page 769
17. Franchimont PG, De Doncker P, Van de Velde V, Jacqmim P, Arrese JE, Pierard GE. Paradoxical response to itraconazole treatment in a patient with onychomycosis caused by Microsporum gypseum. Ann Soc Belg Med Trop. 1995;75:211-7.

18. Peeters J, Neeskens P, Tollenaeae JP, Van Remoortere P, Brewster ME. Characterization of the interaction of 2-hydroxypropyl-beta-cyclodextrin with itraconazole at pH 2, 4, and 7. J Pharm Sci. 2002;91:1414-22.

19. Shargel L, Andrew BC, Wu-Pong S. Applied biopharmaceutics and pharmacokinetics. Stamford: Appleton and Lange; 1999.

20. Ramesh V, Meenakshi S, Jyothirmayee N, Bullebbai M, Noorjahan SK, Rajeswar G. Enhancement of solubility, dissolution rate and bioavailability of BCS class II drugs. Int J Pharma Chem Res. 2016;2:80-95.

21. Baert LEC, Verreck G, Thone D. Antifungal compositions with improved bioavailability. US Patent; 2003: US 6,509,038 B2.

22. Sirisha KVR, Sri KV, Suresh K, Reddy GK. Devanna N. A review of pellets and pelletization process-a multiparticulate drug delivery system. Int J Pharm Sci Res. 2013;4:2145-58.

23. Uppoor VR. Regulatory perspectives on in vitro (dissolution)/in vivo (bioavailability) correlations. J Control Release. 2001;72:127-32.

24. Guidance for Industry: Dissolution testing of immediate-release solid oral dosage forms. Food and Drug Administration, Center for Drug Evaluation and Research (CDER). United States Food and Drug Administration; 1997.

25. Singla N, Gupta GD, Kohli K, Singla AK. A discriminatory and biorelevant dissolution test method for simvastatin drug products. Dissolution Technol. 2009;16:11-3.

26. Taupitz T, Klein S. Can biorelevant media be simplified by using SLS and tween 80 to replace bile compounds. Open Drug Deliv J. 2010;4:30-7.

27. Sardana K, Khurana A, Singh A, Gautam RK. A pilot analysis of morphometric assessment of itraconazole brands using dermoscopy and its relevance in the current scenario. Indian Dermatol Online J. 2018;9:426-31.

28. Kapoor BS, Subbaro GV. Formulation development and characterization of itraconazole granules. Int J Pharm Sci Nanotechnol. 2011;4:1497-500.

29. Swaminathan S, Sangwai M, Wawdhane S, Vavia P. Soluble itraconazole in tablet form using disordered drug delivery approach: Critical scale-up considerations and bio equivalence studies. AAPS Pharm Sci Tech. 2013;14:360-74.

Cite this article as: Verma R, Hodge S, Gargote C, Modi P, Upreti N, Yadav L, et al. Assessment of physical and dissolution characteristics of various itraconazole capsule formulations: a comparative analysis. Int J Res Dermatol 2019;5:765-70.